Cited 3 times in
Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2019-03-15T02:25:50Z | - |
dc.date.available | 2019-03-15T02:25:50Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167474 | - |
dc.description.abstract | BACKGROUND & AIMS: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). METHODS: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. RESULTS: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). CONCLUSIONS: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Soo Kim | - |
dc.contributor.googleauthor | Oidov Baatarkhuu | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kijun Song | - |
dc.contributor.googleauthor | Kwang‐Hyub Han | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.identifier.doi | 10.1111/liv.13948 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J02171 | - |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.pmid | 30280461 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13948 | - |
dc.subject.keyword | fibrosis | - |
dc.subject.keyword | hepatitis B | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | matching | - |
dc.subject.keyword | prognosis | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 81 | - |
dc.citation.endPage | 89 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, Vol.39(1) : 81-89, 2019 | - |
dc.identifier.rimsid | 39813 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.